Systematic review of societal costs associated with stroke, bleeding and monitoring in atrial fibrillation

Economic consequences associated with the rise in nonvitamin K antagonist oral anticoagulant use on a societal level remain unclear. Evidence from the past decade on the societal economic burden associated with stroke, bleeding and international normalized ratio monitoring in atrial fibrillation was...

Full description

Saved in:
Bibliographic Details
Published in:Journal of comparative effectiveness research 2019-10, Vol.8 (14), p.1147-1166
Main Authors: Martin, Amber L, Reeves, Alessandra G, Berger, Samantha E, Fusco, Manuela Di, Wygant, Gail D, Savone, Mirko, Snook, Kassandra, Nejati, Mina, Lanitis, Tereza
Format: Article
Language:English
Subjects:
Anticoagulants
atrial fibrillation
Cardiac arrhythmia
Clinical trials
Cost analysis
Cost estimates
costs
Disease
Disease prevention
Drug dosages
Health care expenditures
Hospital costs
indirect costs
INR monitoring
major bleeding
Patients
Stroke
Studies
Systematic review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Economic consequences associated with the rise in nonvitamin K antagonist oral anticoagulant use on a societal level remain unclear. Evidence from the past decade on the societal economic burden associated with stroke, bleeding and international normalized ratio monitoring in atrial fibrillation was collected and summarized through a systematic literature review. There were 14 studies identified that reported indirect costs, which were highest among patients with hemorrhagic stroke and intracranial hemorrhage. The contribution of indirect costs to the total was marginal during acute treatment but substantially increased (30–50%) 2 years after stroke and bleeding events. Limited data were available on societal costs in atrial fibrillation and further research is warranted.
ISSN:2042-6305
2042-6313
DOI:10.2217/cer-2019-0089